SCHEMBL7935670

SCHEMBL7935670

CCN(C)c1nc2ccccc2nc1C=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
CREBBP Q92793 1/20 0.37
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.36
HPGD P15428 2/20 0.36
GAA P10253 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
EGLN1 Q9GZT9 2/20 0.34
MAPT P10636 2/20 0.34
RAB9A P51151 1/20 0.34
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ACP1 P24666 1/20 0.33
PRMT5 O14744 1/20 0.33
CYP1A2 P05177 1/20 0.33
MAT2A P31153 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2046631 0.82 KDM4E (0.42) TSHRALDH1A1LMNAHPGDGAA
SCHEMBL7937705 0.82 GAA (0.34) ALOX15TSHRCREBBPALDH1A1LMNA
SCHEMBL7938614 0.74 KMT2A (0.50) TSHRALDH1A1LMNAGAAMEN1
SCHEMBL7327853 0.74 KMT2A (0.51) ALOX15TSHRCREBBPALDH1A1GAA
SCHEMBL2024127 0.72 KDM4E (0.46) ALDH1A1LMNAHPGDGAAMEN1
SCHEMBL2023434 0.69 ERN1 (0.49) TSHRALDH1A1HPGDGAAMEN1
SCHEMBL7926375 0.68 ALDH1A1 (0.60) ALDH1A1LMNAGAAMEN1KMT2A
SCHEMBL3706723 0.65 TDP1 (0.58) ALDH1A1HPGDGAAMEN1KMT2A
SCHEMBL5101956 0.65 MAPT (0.44) ALOX15ALDH1A1LMNAHPGDGAA
SCHEMBL20551851 0.65 MAPT (0.42) ALDH1A1LMNAHPGDGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
WO-2010027097-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE10A, PDE12, PDE9A ALOX15 3693/4885TSHR 3644/4885CREBBP 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.